Life Technologies to Invest $18 Million in Facility Expansion and Current Good Manufacturing Practice Compliance Plan

Life Technologies to Invest $18 Million in Facility Expansion and Current Good
                    Manufacturing Practice Compliance Plan

Project aims to broaden product offerings to growing diagnostics and
pharmaceutical customer base

PR Newswire

CARLSBAD, Calif., March 28, 2013

CARLSBAD, Calif., March 28, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announces plans to invest $18 million in a multi-phase
plan to expand its facility in Pleasanton, Calif., where it will implement
Current Good Manufacturing Practice (cGMP) capabilities for its genetic
analysis products. The project, which executes against Life's roadmap to
broaden its offerings in the growing molecular diagnostics market, will break
ground in the second quarter of 2013. The expanded facility will provide
accessibility for customers on a global scale and enable more efficient
business continuity planning.

"As a provider of molecular companion diagnostic development and testing for
the pharmaceutical and biotech industries, it is paramount that we have access
to trustworthy oligos products that meet GMP compliance," said Byung-in Lee,
Ph.D., MBA,  Senior Director, Research & Development for AltheaDx. "Reagents
such as those planned in Life Technologies' new manufacturing facility are
essential for meeting regulatory requirements and will help speed up our
companion diagnostic development and validation process."

The Pleasanton facility currently manufactures TaqMan® assays, GeneArt® and
Ion AmpliSeq™ product lines and other widely used reagents that are part of
Life Technologies' genetic analysis portfolio. The first phase of the project
will repurpose 10,000 square feet of space to manufacture molecular probes and
primers under cGMP standards. Subsequent phased expansions totaling an
additional 30,000 square feet will follow over the next one-to-three years to
produce regulatory-compliant materials for qPCR workflows in the clinical

"We are committed to providing the highest quality products that help meet the
specific needs of our growing diagnostic and pharmaceutical customer base,"
said Mark Stevenson, President and COO of Life Technologies. "The expansion of
our Pleasanton facility and plan to achieve cGMP certification underscores our
growth strategy in new markets and our commitment to win in genetic analysis
from discovery to diagnostics."

Products manufactured in cGMP-certified facilities ensure their quality meets
standards of control for use in the pharmaceutical and medical fields. Life
Technologies currently has nine facilities that follow cGMP standards and are
ISO 9001/13485-compliant for the manufacture of a broad spectrum of products,
including instruments, various reagents, assays, cell culture media and sera.

About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions are secured by more than 5,000
patents and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.


Life Technologies Contact
Mauricio Minotta
760-805-5266 (mobile)

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.